scholarly journals Clear Cell Carcinoma of the Endometrium in a Patient Presenting with Postmenopausal Bleeding but Negative Endometrial Biopsy

2021 ◽  
pp. 1768-1772
Author(s):  
Swechchha Silwal ◽  
Sumeet Kumar Yadav ◽  
Benedict Amalraj ◽  
Mohamed Mandeel ◽  
Geetha Krishnamoorthy
Keyword(s):  
Endometrial Cancer ◽  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Endometrial Thickness ◽  
Transvaginal Ultrasound ◽  
Endometrial Biopsy ◽  
Postmenopausal Bleeding ◽  
Gynecological Malignancy ◽  
The Usa

Endometrial carcinoma is the most common gynecological malignancy in the USA with approximately 66,570 cases and 12,940 deaths in 2020. Clear cell carcinoma (CCC) of the endometrium is an estrogen-independent type II endometrial cancer which accounts for <5% of endometrial cancer. When diagnosed roughly, 45% of patients have extrauterine metastases. Current American College of Obstetrics and Gynecology guidelines recommend transvaginal ultrasound for postmenopausal bleeding and a biopsy for those with endometrial thickness >5 mm. However, we present a case of a postmenopausal woman with a history of fibroid where endometrial biopsy has failed to make diagnosis twice. Hence, further testing should be performed in patients with unexplained postmenopausal bleeding including vaginal hysterectomy with lymph node dissection.

Value of endometrial thickness assessed by transvaginal ultrasound for the prediction of endometrial cancer in patients with postmenopausal bleeding

2017 ◽  
Vol 296 (2) ◽  
pp. 319-326 ◽  
Author(s):  
Amelie Schramm ◽  
Florian Ebner ◽  
Emanuel Bauer ◽  
Wolfgang Janni ◽  
Ulrike Friebe-Hoffmann ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Endometrial Thickness ◽  
Transvaginal Ultrasound ◽  
Postmenopausal Bleeding

scholarly journals A clear cancer cell line (150057) derived from human endometrial carcinoma harbors two novel mutations

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Yu-Hsun Chang ◽  
Dah-Ching Ding
Keyword(s):  
Endometrial Cancer ◽  
Cell Carcinoma ◽  
Cell Line ◽  
Cell Lines ◽  
Cancer Cell ◽  
Clear Cell ◽  
Carcinoma Cell ◽  
Clear Cell Carcinoma ◽  
Carcinoma Cell Line ◽  
Novel Mutations

Abstract Background Cell lines are extremely useful for both basic and clinical research. Thus, establishing endometrial cancer cell lines with malignant histology is important. This study aimed to extensively characterize an endometrial clear cell carcinoma cell line. Methods This cell line, named 150,057, was derived from the endometrial clear cell cancer of a 63-year-old woman. The morphology, chromosomes, chemosensitivity, tumor markers, xenotransplantation characteristics, and cancer-related genes of the cell line were characterized. Results This cell line exhibited adequate growth, being passaged more than 70 times. The morphology of the cells was polygonal with a cobblestone-like appearance. Karyotyping of the cell line revealed a hypodiploid chromosomal number. 150057 cells expressed CA19–9 and CA125. The cell line was sensitive to doxorubicin, paclitaxel, carboplatin, and cisplatin. After the cells were transplanted into the subcutaneous region of non-obese diabetic-severe combined immunodeficiency mice, they generated xenograft tumors with similar histology as the original tumor. A total of 59 somatic nucleotide mutations were identified in 25 of the 53 examined tumor suppressor genes and oncogenes. Two novel mutations were found in FGFR3 and ARID1A. Conclusion We established and characterized an endometrial clear cell carcinoma cell line that may be useful in carcinogenesis and treatment research for endometrial cancer.

scholarly journals Clear Cell Carcinoma of Endometrium: A Clinical Review

2014 ◽  
Vol 2 (1) ◽  
pp. 15-19
Author(s):  
Rajani Rawat ◽  
Soniya Vishwakarma ◽  
Shikha Seth ◽  
Vaibhav Kanti ◽  
Pragati Mishra
Keyword(s):  
Endometrial Cancer ◽  
Cell Carcinoma ◽  
Clinical Review ◽  
Pap Smear ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Clinical Staging ◽  
Transvaginal Sonography ◽  
Histopathological Diagnosis ◽  
Management Protocol

ABSTRACT Clear cell carcinoma of endometrium is a rare (1-6%) but aggressive malignancy with high propensity of early extra-uterine spread. The usual presentation is postmenopausal bleeding and discharge as with other endometrial cancers but it does not have preceding hyperplastic stage, instead it develops from thin atrophic endometrium, therefore impossible to identify by the screening measures like Pap smear and transvaginal sonography. First step for early diagnosis of such unfavorable endometrial cancer should be endometrial biopsy. Histopathological diagnosis is mandatory to confirm the clear cells present in the endometrial sample before planning the management. Clinical staging is highly erroneous in clear cell endometrial cancer and should not be taken into consideration in management plan. Being a rare cancer, there is lack of true evidence on its management protocol. Here, we had tried to provide the review about the clear cell endometrial (CCE) cancer diagnosis and management along with a case report for clinical perspective. How to cite this article Seth S, Rawat R, Kanti V, Mishra P, Vishwakarma S. Clear Cell Carcinoma of Endometrium: A Clinical Review. J South Asian Feder Menopause Soc 2014;2(1):15-19.

scholarly journals DEveloping Tests for Endometrial Cancer deTection (DETECT): protocol for a diagnostic accuracy study of urine and vaginal samples for the detection of endometrial cancer by cytology in women with postmenopausal bleeding

BMJ Open ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. e050755
Author(s):  
Eleanor R Jones ◽  
Suzanne Carter ◽  
Helena O'Flynn ◽  
Kelechi Njoku ◽  
Chloe E Barr ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Diagnostic Accuracy ◽  
Cancer Detection ◽  
Transvaginal Ultrasound ◽  
Primary Objective ◽  
Endometrial Biopsy ◽  
Test Accuracy ◽  
Diagnostic Accuracy Study ◽  
Postmenopausal Bleeding ◽  
Accuracy Study

IntroductionPostmenopausal bleeding (PMB), the red flag symptom for endometrial cancer, triggers urgent investigation by transvaginal ultrasound scan, hysteroscopy and/or endometrial biopsy. These investigations are costly, invasive and often painful or distressing for women. In a pilot study, we found that voided urine and non-invasive vaginal samples from women with endometrial cancer contain malignant cells that can be identified by cytology. The aim of the DEveloping Tests for Endometrial Cancer deTection (DETECT) Study is to determine the diagnostic test accuracy of urine and vaginal cytology for endometrial cancer detection in women with PMB.Methods and analysisThis is a multicentre diagnostic accuracy study of women referred to secondary care with PMB. Eligible women will be asked to provide a self-collected voided urine sample and a vaginal sample collected with a Delphi screener before routine clinical procedures. Pairs of specialist cytologists, blinded to participant cancer status, will assess and classify samples independently, with differences settled by consensus review or involving a third cytologist. Results will be compared with clinical outcomes from standard diagnostic tests. A sample size of 2000 women will have 80% power to establish a sensitivity of vaginal samples for endometrial cancer detection by cytology of ≥85%±7%, assuming 5% endometrial cancer prevalence. The primary objective is to determine the diagnostic accuracy of urogenital samples for endometrial cancer detection by cytology. Secondary objectives include the acceptability of urine and vaginal sampling to women.Ethics and disseminationThis study has been approved by the North West–Greater Manchester West Research Ethics Committee (16/NW/0660) and the Health Research Authority. Results will be disseminated through publication in peer-reviewed scientific journals, presentation at conferences and via charity websites.Trial registration numberISRCTN58863784.

scholarly journals A RARE CASE OF CLEAR CELL CARCINOMA OF ENDOMETRIUM IN A POST-MENOPAUSAL WOMAN- A HISTOPATHOLOGICAL CASE REPORT

2021 ◽  
pp. 10-11
Author(s):  
Joyeeta Mandal ◽  
Manoj Kumar Paswan ◽  
Arpana Shailaly Tirkey ◽  
Sona Pathak
Keyword(s):  
Cell Carcinoma ◽  
Vaginal Bleeding ◽  
Pap Smear ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Relevant Literature ◽  
Endometrial Biopsy ◽  
Menopausal Woman ◽  
Histopathological Diagnosis ◽  
Post Menopausal

Clear cell carcinoma of endometrium is a rare but aggressive malignancy with high predisposition of early extra-uterine spread. It commonly presents with vaginal bleeding or discharge. Less commonly, it may be diagnosed subsequent to an abnormal pap smear. Endometrial biopsy is ideally the first step for early diagnosis of such unfavourable endometrial cancer. Histopathological diagnosis is mandatory to confirm the presence of clear cells in the endometrial sample before planning the course of treatment. Here, we report a case of a postmenopausal woman who presented with vaginal bleeding without a specific medical history. Endometrial biopsy was done and sample was sent to our department of Pathology for histopathological diagnosis. We report the case from a histopathological perspective with a brief review of the relevant literature.

Hysteroscopy in the diagnosis of postmenopausal bleeding

2007 ◽  
Vol 13 (3) ◽  
pp. 132-134 ◽  
Author(s):  
Bramara Guruwadayarhalli ◽  
Siân E Jones ◽  
Vyjayanthi Srinivasan
Keyword(s):  
Gold Standard ◽  
Hospital Admissions ◽  
Endometrial Thickness ◽  
Transvaginal Ultrasound ◽  
Endometrial Biopsy ◽  
Postmenopausal Bleeding ◽  
First Line ◽  
Endometrial Cavity ◽  
Outpatient Hysteroscopy ◽  
Transvaginal Ultrasound Scan

Postmenopausal bleeding (PMB) accounts for 5% of gynaecology referrals. Investigations should exclude malignancy and pre-malignancy, and diagnose the benign conditions that need treatment. The three modalities that are most commonly used are transvaginal ultrasound scan (TVS), endometrial biopsy (EB) and hysteroscopy. Most authors agree that the first-line investigation should be TVS, followed by endometrial assessment (EB or hysteroscopy) if the endometrial thickness is >4 mm. When scanning demonstrates the possibility of pathology, outpatient hysteroscopy and biopsy are the gold standard for investigating the endometrial cavity. Focal pathology can be removed during the hysteroscopy, thereby reducing hospital admissions and costs.

Delayed Pancreatic Metastasis of Renal Clear Cell Carcinoma

2013 ◽  
Vol 13 (2) ◽  
pp. 79-80
Author(s):  
Zane Simtniece ◽  
Gatis Kirsakmens ◽  
Ilze Strumfa ◽  
Andrejs Vanags ◽  
Maris Pavars ◽  
...  
Keyword(s):  
Abdominal Pain ◽  
Surgical Treatment ◽  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Primary Tumour ◽  
Renal Clear Cell Carcinoma ◽  
Pancreatic Metastasis ◽  
Distal Pancreatic Resection

Abstract Here, we report surgical treatment of a patient presenting with pancreatic metastasis (MTS) of renal clear cell carcinoma (RCC) 11 years after nephrectomy. RCC is one of few cancers that metastasise in pancreas. Jaundice, abdominal pain or gastrointestinal bleeding can develop; however, asymptomatic MTS can be discovered by follow-up after removal of the primary tumour. The patient, 67-year-old female was radiologically diagnosed with a clinically silent mass in the pancreatic body and underwent distal pancreatic resection. The postoperative period was smooth. Four months after the surgery, there were no signs of disease progression.

Sign in / Sign up

Export Citation Format

Share Document